A systematic review and meta-Analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem- resistant pseudomonas aeruginosa

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2626-2637

  Voor, Anne F ^a   Severin, Juliëtte A ^a   Lesaffre, Emmanuel M E H ^a,b   Vos, Margreet C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KU LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; CORTICOSTEROID; QUINOLONE; QUINOLONE DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ARTIFICIAL VENTILATION; CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA; CASE CONTROL STUDY; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; EMBASE; FOLLOW UP; HEALTH CARE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MEDICAL DEVICE; MEDLINE; META ANALYSIS; NONHUMAN; PATIENT HISTORY OF TRANSPLANTATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PUBLICATION; QUALITY CONTROL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; URINARY CATHETER; ANTIBIOTIC RESISTANCE; DRUG EFFECTS;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; PSEUDOMONAS AERUGINOSA; RISK FACTORS;

EID: 84898656042     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01758-13     Document Type: Review

References (108)

1. Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, Leblebicioglu H, Fisher D, Alvarez-Moreno C, Khader IA, Del Rocio Gonzalez Martinez M, Cuellar LE, Navoa-Ng JA, Abouqal R, Guanche Garcell H, Mitrev Z, Pirez Garcia MC, Hamdi A, Duenas L, Cancel E, Gurskis V, Rasslan O, Ahmed A, Kanj SS, Ugalde OC, Mapp T, Raka L, Yuet Meng C, Thu le TA, Ghazal TAS, Gikas A, Narvaez LP, Mejia N, Hadjieva N, Gamar Elanbya MO, Guzman Siritt ME, Jayatilleke K. 2012. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am. J. Infect. Control 40:396-407. http://dx.doi.org/10.1016/j.ajic.2011.05.020.
2. Carmeli Y, Troillet N, Karchmer AW, Samore MH. 1999. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch. Intern. Med. 159:1127-1132. http://dx.doi.org/10.1001/archinte.159.10.1127.
3. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FSL, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GKS, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock REW, Lory S, Olson MV. 2000. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959-964. http://dx.doi.org/10.1038/35023079.
4. Suarez C, Pena C, Gavalda L, Tubau F, Manzur A, Dominguez MA, Pujol M, Gudiol F, Ariza J. 2010. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int. J. Infect. Dis. 14(Suppl 3):e73-e78. http://dx.doi.org/10.1016/j.ijid.2009.11.019.
5. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. 2011. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 19:419-426. http://dx.doi.org/10.1016/j.tim.2011.04.005.
6. Bradford PA. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. table of contents. http://dx.doi.org/10.1128/CMR.14.4.933-951.2001.
7. Jacoby GA, Munoz-Price LS. 2005. The new beta-lactamases. N. Engl. J. Med. 352:380-391. http://dx.doi.org/10.1056/NEJMra041359.
8. Walsh TR. 2008. Clinically significant carbapenemases: an update. Curr. Opin. Infect. Dis. 21:367-371. http://dx.doi.org/10.1097/QCO.0b013e328303670b.
9. Camargo CH, Bruder-Nascimento A, Mondelli AL, Montelli AC, Sadatsune T. 2011. Detection of SPM and IMP metallo-beta-lactamases in clinical specimens of Pseudomonas aeruginosa from a Brazilian public tertiary hospital. Braz. J. Infect. Dis. 15:478-481. http://dx.doi.org/10.1016/S1413-8670(11)70231-8.
10. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. 2005. First nosocomial outbreak of Pseudomonas aeruginosa producing an integronborne metallo-beta-lactamase (VIM-2) in the United States. Antimicrob. Agents Chemother. 49:3538-3540. http://dx.doi.org/10.1128/AAC.49.8.3538-3540.2005.
11. Van der Bij AK, Van der Zwan D, Peirano G, Severin JA, Pitout JD, Van Westreenen M, Goessens WH. 2012. Metallo-beta-lactamaseproducing Pseudomonas aeruginosa in the Netherlands: the nationwide emergence of a single sequence type. Clin. Microbiol. Infect. 18:E369-E372. http://dx.doi.org/10.1111/j.1469- 0691.2012.03969.x.
12. Van der Bij AK, Van Mansfeld R, Peirano G, Goessens WH, Severin JA, Pitout JD, Willems R, Van Westreenen M. 2011. First outbreak of VIM-2 metallo-beta-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes. Int. J. Antimicrob. Agents 37:513-518. http://dx.doi.org/10.1016/j.ijantimicag.2011.02.010.
13. Zhang R, Mingcheng L, Dong X, Li F. 2011. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa carrying blaVIM-2 in burn wards, China. Braz. J. Infect. Dis. 15:505-506. http://dx.doi.org/10.1016/S1413- 8670(11)70241-0.
14. Suarez C, Pena C, Arch Dominguez OMA, Tubau F, Juan C, Gavalda L, Sora M, Oliver A, Pujol M, Ariza J. 2011. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect. Dis. 11:272. http://dx.doi.org/10.1186/1471- 2334-11-272.
15. Falagas ME, Kopterides P. 2006. Risk factors for the isolation of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J. Hosp. Infect. 64:7-15. http://dx.doi.org/10.1016/j.jhin.2006.04.015.
16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. 2009. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol. 62:e1-e34. http://dx.doi.org/10.1016/j.jclinepi.2009.06.006.
17. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, Noreddin AM, Karlowsky JA. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052. http://dx.doi.org/10.2165/00003495-200767070-00006.
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. 2008. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J. Clin. Epidemiol. 61:344-349. http://dx.doi.org/10.1016/j.jclinepi.2007.11.008.
19. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. 2011. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-Analyses. Ottawa Hospital Research Institute, Ottawa, Canada.
20. DerSimonian R, Laird N. 1986. Meta-Analysis in clinical trials. Control Clin. Trials 7:177-188. http://dx.doi.org/10.1016/0197-2456(86)90046-2.
21. Kwint HM, van der Linden PD, Roukens MM, Natsch S. 2012. Intensification of antibiotic use within acute care hospitals in the Netherlands. J. Antimicrob. Chemother. 67:2283-2288. http://dx.doi.org/10.1093/jac/dks190.
22. Liew YX, Krishnan P, Yeo CL, Tan TY, Lee SY, Lim WP, Lee W, Hsu LY. 2011. Surveillance of broad-spectrum antibiotic prescription in Singaporean hospitals: a 5-year longitudinal study. PLoS One 6:e28751. http://dx.doi.org/10. 1371/journal.pone.0028751.
23. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P. 2010. Dramatic increase of third-generation cephalosporin-resistant E. coli in German intensive care units: secular trends in antibiotic drug use and bacterial resistance, 2001 to 2008. Crit. Care 14:R113. http://dx.doi.org/10.1186/cc9062.
24. Pluss-Suard C, Pannatier A, Kronenberg A, Muhlemann K, Zanetti G. 2011. Hospital antibiotic consumption in Switzerland: comparison of a multicultural country with Europe. J. Hosp. Infect. 79:166-171. http://dx.doi.org/10.1016/j. jhin.2011.05.028.
25. Fortaleza CM, Freire MP, Filho Dde C, de Carvalho Ramos M. 2006. Risk factors for recovery of imipenem-or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil. Infect. Control Hosp. Epidemiol. 27:901-906. http://dx.doi.org/10.1086/507288.
26. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. 2002. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin. Infect. Dis. 34:340-345. http://dx.doi.org/10.1086/338237.
27. Onguru P, Erbay A, Bodur H, Baran G, Akinci E, Balaban N, Cevik MA. 2008. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections. J. Korean Med. Sci. 23:982-987. http://dx.doi.org/10.3346/jkms.2008. 23.6.982.
28. Brugha RE, Davies JC. 2011. Pseudomonas aeruginosa in cystic fibrosis: pathogenesis and new treatments. Br. J. Hosp. Med. (Lond.) 72:614-619.
29. von Eiff C, Jansen B, Kohnen W, Becker K. 2005. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 65:179-214. http://dx.doi.org/10.2165/00003495-200565020-00003.
30. Beovic B, Kreft S, Seme K, Cizman M. 2009. The impact of total control of antibiotic prescribing by infectious disease specialist on antibiotic consumption and cost. J. Chemother. 21:46-51. http://dx.doi.org/10.1179/joc. 2009.21.1.46.
31. Kerremans JJ, Verbrugh HA, Vos MC. 2012. Frequency of microbiologically correct antibiotic therapy increased by infectious disease consultations and microbiological results. J. Clin. Microbiol. 50:2066-2068. http://dx.doi.org/10. 1128/JCM.06051-11.
32. Lo E, Rezai K, Evans AT, Madariaga MG, Phillips M, Brobbey W, Schwartz DN, Wang Y, Weinstein RA, Trenholme GM. 2004. Why don't they listen? Adherence to recommendations of infectious disease consultations. Clin. Infect. Dis. 38:1212-1218. http://dx.doi.org/10.1086/383315.
33. Harris AD, Johnson JK, Thom KA, Morgan DJ, McGregor JC, Ajao AO, Moore AC, Comer AC, Furuno JP. 2011. Risk factors for development of intestinal colonization with imipenem-resistant Pseudomonas aeruginosa in the intensive care unit setting. Infect. Control Hosp. Epidemiol. 32:719-722. http://dx.doi.org/10.1086/660763.
34. Lautenbach E, Synnestvedt M, Weiner MG, Bilker WB, Vo L, Schein J, Kim M. 2010. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31:47-53. http://dx.doi.org/10.1086/649021.
35. Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, Lucet JC, Corvec S. 2010. Imipenem-resistant Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. Diagn. Microbiol. Infect. Dis. 66:1-6. http://dx.doi.org/10.1016/j.diagmicrobio. 2009.08.014.
36. Cezario RC, Duarte De Morais L, Ferreira JC, Costa-Pinto RM, da Costa Darini AL, Gontijo-Filho PP. 2009. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital. Enferm. Infecc. Microbiol. Clin. 27:269-274. http://dx.doi.org/10.1016/j.eimc.2008.09.009.
37. Mueller MR, Hayden MK, Fridkin SK, Warren DK, Phillips L, Lolans K, Quinn JP. 2008. Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis. Eur. J. Clin. Microbiol. Infect. Dis. 27:565-570. http://dx.doi.org/10.1007/s10096-008-0475- 9.
38. Pena C, Guzman A, Suarez C, Dominguez MA, Tubau F, Pujol M, Gudiol F, Ariza J. 2007. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenemresistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob. Agents Chemother. 51:1967-1971. http://dx.doi.org/10.1128/AAC.01483-06.
39. Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, Nanas S, Paniara O, Roussos C, Giamarellos-Bourboulis E, Routsi C, Zakynthinos SG. 2007. Prolonged use of carbapenems and colistin predisposes to ventilator-Associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med. 33: 1524-1532. http://dx.doi.org/10.1007/s00134-007-0683-2.
40. Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V, Dvorak T, Hogan H, Hachem R, Rolston K, Raad I. 2005. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104:205-212. http://dx.doi.org/10.1002/cncr.21115.
41. Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN. 2005. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 31:870-873. http://dx.doi.org/10.1016/j.burns.2005.04.015.
42. Zavascki AP, Cruz RP, Goldani LZ. 2005. Risk factors for imipenemresistant Pseudomonas aeruginosa: a comparative analysis of two casecontrol studies in hospitalized patients. J. Hosp. Infect. 59:96-101. http://dx.doi.org/10.1016/j.jhin.2004.09.007.
43. Cao B, Wang H, Sun H, Zhu Y, Chen M. 2004. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J. Hosp. Infect. 57:112-118. http://dx.doi.org/10.1016/j.jhin.2004.03.021.
44. Troillet N, Samore MH, Carmeli Y. 1997. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25:1094-1098. http://dx.doi.org/10.1086/516092.
45. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.
46. Lodise TP, Jr, Miller C, Patel N, Graves J, McNutt LA. 2007. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates. Infect. Control Hosp. Epidemiol. 28:959-965. http://dx.doi.org/10.1086/518972.
47. Montero M, Sala M, Riu M, Belvis F, Salvado M, Grau S, Horcajada JP, Alvarez-Lerma F, Terradas R, Orozco-Levi M, Castells X, Knobel H. 2010. Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case-control study. Eur. J. Clin. Microbiol. Infect. Dis. 29:335-339. http://dx.doi.org/10.1007/s10096-009-0850-1.
48. Kohlenberg A, Weitzel-Kage D, van der Linden P, Sohr D, Vogeler S, Kola A, Halle E, Ruden H, Weist K. 2010. Outbreak of carbapenemresistant Pseudomonas aeruginosa infection in a surgical intensive care unit. J. Hosp. Infect. 74:350-357. http://dx.doi.org/10.1016/j.jhin.2009.10.024.
49. Pena C, Suarez C, Tubau F, Dominguez A, Sora M, Pujol M, Gudiol F, Ariza J. 2009. Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 28:519-522. http://dx.doi.org/10.1007/s10096-008-0645-9.
50. Yang K, Zhuo H, Guglielmo BJ, Wiener-Kronish J. 2009. Multidrugresistant Pseudomonas aeruginosa ventilator-Associated pneumonia: the role of endotracheal aspirate surveillance cultures. Ann. Pharmacother. 43:28-35. http://dx.doi.org/10.1345/aph.1L210.
51. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. 2006. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 27:893-900. http://dx.doi.org/10.1086/507274.
52. Zavascki AP, Barth AL, Gaspareto PB, Goncalves AL, Moro AL, Fernandes JF, Goldani LZ. 2006. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals. J. Antimicrob. Chemother. 58:882-885. http://dx.doi.org/10.1093/jac/ dkl327.
53. Nouer SA, Nucci M, de-Oliveira MP, Pellegrino FL, Moreira BM. 2005. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob. Agents Chemother. 49:3663-3667. http://dx.doi.org/10.1128/AAC.49.9.3663-3667.2005.
54. Defez C, Fabbro-Peray P, Bouziges N, Gouby A, Mahamat A, Daures JP, Sotto A. 2004. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J. Hosp. Infect. 57:209-216. http://dx.doi.org/10.1016/j.jhin.2004. 03.022.
55. Furtado GH, Gales AC, Perdiz LB, Santos AE, Wey SB, Medeiros EA. 2010. Risk factors for hospital-Acquired pneumonia caused by imipenem-resistant Pseudomonas aeruginosa in an intensive care unit. Anaesth. Intensive Care 38:994-1001.
56. Martinez JA, Delgado E, Marti S, Marco F, Vila J, Mensa J, Torres A, Codina C, Trilla A, Soriano A, Alquezar A, Castro P, Nicolas JM. 2009. Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients. Intensive Care Med. 35:439-447. http://dx.doi.org/10.1007/s00134-008-1326-y.
57. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. 2006. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob. Agents Chemother. 50:43-48. http://dx.doi.org/10.1128/AAC.50.1.43- 48.2006.
58. Richard P, Le Floch R, Chamoux C, Pannier M, Espaze E, Richet H. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J. Infect. Dis. 170:377-383. http://dx.doi.org/10.1093/infdis/170.2.377.
59. Nagao M, Iinuma Y, Igawa J, Saito T, Yamashita K, Kondo T, Matsushima A, Takakura S, Takaori-Kondo A, Ichiyama S. 2011. Control of an outbreak of carbapenem-resistant Pseudomonas aeruginosa in a haemato-oncology unit. J. Hosp. Infect. 79:49-53. http://dx.doi.org/10.1016/j.jhin.2011.04.018.
60. Park YS, Lee H, Chin BS, Han SH, Hong SG, Hong SK, Kim HY, Uh Y, Shin HB, Choo EJ, Song W, Jeong SH, Lee K, Kim JM. 2011. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems. J. Hosp. Infect. 79:54-58. http://dx.doi.org/10.1016/j.jhin.2011.05.014.
61. Cortes JA, Cuervo SI, Urdaneta AM, Potdevin G, Arroyo P, Bermudez D, Correa A, Villegas MV. 2009. Identifying and controlling a multiresistant Pseudomonas aeruginosa outbreak in a Latin-American cancer centre and its associated risk factors. Braz. J. Infect. Dis. 13:99-103.
62. Fortaleza CM, Figueiredo LC, Beraldo CC, Melo EC, Pola PM, Aragao VD. 2009. Risk factors of oropharyngeal carriage of Pseudomonas aeruginosa among patients from a medical-surgical intensive care unit. Braz. J. Infect. Dis. 13:173-176. http://dx.doi.org/10.1590/S1413-86702009000300004.
63. Pereira GH, Levin AS, Oliveira HB, Moretti ML. 2008. Controlling the clonal spread of Pseudomonas aeruginosa infection. Infect. Control Hosp. Epidemiol. 29:549-552. http://dx.doi.org/10.1086/588163.
64. Dropulic LK, Leslie JM, Eldred LJ, Zenilman J, Sears CL. 1995. Clinical manifestations and risk factors of Pseudomonas aeruginosa infection in patients with AIDS. J. Infect. Dis. 171:930-937. http://dx.doi.org/10.1093/infdis/171.4. 930.
65. Talon D, Capellier G, Boillot A, Michel-Briand Y. 1995. Use of pulsedfield gel electrophoresis as an epidemiologic tool during an outbreak of Pseudomonas aeruginosa lung infections in an intensive care unit. Intensive Care Med. 21:996-1002. http://dx.doi.org/10.1007/BF01700661.
66. Thuong M, Arvaniti K, Ruimy R, de la Salmoniere P, Scanvic-Hameg A, Lucet JC, Regnier B. 2003. Epidemiology of Pseudomonas aeruginosa and risk factors for carriage acquisition in an intensive care unit. J. Hosp. Infect. 53:274-282. http://dx.doi.org/10.1053/jhin.2002.1370.
67. Eagye KJ, Kuti JL, Nicolau DP. 2009. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 30:746-752. http://dx.doi.org/10.1086/603527.
68. Furtado GH, Bergamasco MD, Menezes FG, Marques D, Silva A, Perdiz LB, Wey SB, Medeiros EA. 2009. Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality. J. Crit. Care 24:625.e9-14. http://dx.doi.org/10.1016/j.jcrc.2009.03.006.
69. Berthelot P, Grattard F, Mahul P, Pain P, Jospe R, Venet C, Carricajo A, Aubert G, Ros A, Dumont A, Lucht F, Zeni F, Auboyer C, Bertrand JC, Pozzetto B. 2001. Prospective study of nosocomial colonization and infection due to Pseudomonas aeruginosa in mechanically ventilated patients. Intensive Care Med. 27:503-512. http://dx.doi.org/10.1007/s001340100870.
70. Mammina C, Di Carlo P, Cipolla D, Casuccio A, Tantillo M, Plano MR, Mazzola A, Corsello G. 2008. Nosocomial colonization due to imipenemresistant Pseudomonas aeruginosa epidemiologically linked to breast milk feeding in a neonatal intensive care unit. Acta Pharmacol. Sin. 29:1486-1492. http://dx.doi.org/10.1111/j.1745-7254.2008.00892.x.
71. Arruda EA, Marinho IS, Boulos M, Sinto SI, Caiaffa HH, Mendes CM, Oplustil CP, Sader H, Levy CE, Levin AS. 1999. Nosocomial infections caused by multiresistant Pseudomonas aeruginosa. Infect. Control Hosp. Epidemiol. 20:620-623. http://dx.doi.org/10.1086/501683.
72. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect. Dis. 38:670-677. http://dx.doi.org/10.1086/381550.
73. Joo EJ, Kang CI, Ha YE, Kang SJ, Park SY, Chung DR, Peck KR, Lee NY, Song JH. 2011. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb. Drug Resist. 17:305-312. http://dx.doi.org/10.1089/mdr.2010.0170.
74. Tumbarello M, Repetto E, Trecarichi EM, Bernardini C, De Pascale G, Parisini A, Rossi M, Molinari MP, Spanu T, Viscoli C, Cauda R, Bassetti M. 2011. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol. Infect. 139: 1740-1749. http://dx.doi.org/10.1017/ S0950268810003055.
75. Yang MA, Lee J, Choi EH, Lee HJ. 2011. Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes. J. Korean Med. Sci. 26:612-618. http://dx.doi.org/10.3346/jkms.2011.26.5.612.
76. Johnson LE, D'Agata EM, Paterson DL, Clarke L, Qureshi ZA, Potoski BA, Peleg AY. 2009. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl. Infect. Dis. 11:227-234. http://dx.doi.org/10.1111/j.1399-3062.2009.00380.x.
77. Tam VH, Chang KT, LaRocco MT, Schilling AN, McCauley SK, Poole K, Garey KW. 2007. Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 58:309-314. http://dx.doi.org/10.1016/j.diagmicrobio.2007.05.006.
78. Falagas ME, Koletsi PK, Kopterides P, Michalopoulos A. 2006. Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrob. Agents Chemother. 50:2541-2543. http://dx.doi.org/10.1128/AAC.00224-06.
79. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW. 2005. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb. Drug Resist. 11:68-74. http://dx.doi.org/10.1089/mdr.2005. 11.68.
80. El Amari EB, Chamot E, Auckenthaler R, Pechere JC, Van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin. Infect. Dis. 33:1859-1864. http://dx.doi.org/10.1086/324346.
81. Hallin M, Deplano A, Roisin S, Boyart V, De Ryck R, Nonhoff C, Byl B, Glupczynski Y, Denis O. 2012. Pseudo-outbreak of extremely drugresistant pseudomonas aeruginosa urinary tract infections due to contamination of an automated urine analyzer. J. Clin. Microbiol. 50:580-582. http://dx.doi.org/10. 1128/JCM.06268-11.
82. Sekiguchi J, Teruya K, Horii K, Kuroda E, Konosaki H, Mizuguchi Y, Araake M, Kawana A, Yoshikura H, Kuratsuji T, Miyazaki H, Kirikae T. 2007. Molecular epidemiology of outbreaks and containment of drugresistant Pseudomonas aeruginosa in a Tokyo hospital. J. Infect. Chemother. 13:418-422. http://dx.doi.org/10.1007/s10156-007-0560-5.
83. Pinna A, Usai D, Sechi LA, Zanetti S, Jesudasan NC, Thomas PA, Kaliamurthy J. 2009. An outbreak of post-cataract surgery endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology 116:2321-2326. e2321-2324. http://dx.doi.org/10.1016/j.ophtha.2009.06.004.
84. Kouda S, Fujiue Y, Watanabe Y, Ohara M, Kayama S, Kato F, Hisatsune J, Tsuruda K, Matsubara A, Doi M, Kuwabara M, Sugai M. 2011. Sporadic isolations of a multi-drug resistant Pseudomonas aeruginosa clone during a 14-month epidemic in a general hospital in Hiroshima. Infection 39:247-253. http://dx.doi.org/10. 1007/s15010-011-0111-y.
85. Babu KV, Kumara A, Vijayanath V. 2011. Study of imipenem resistant metallo-beta-lactamase positive Pseudomonas aeruginosa from different hospital environmental sources. J. Pure Appl. Microbiol. 5:195-203.
86. Crivaro V, Di Popolo A, Caprio A, Lambiase A, Di Resta M, Borriello T, Scarcella A, Triassi M, Zarrilli R. 2009. Pseudomonas aeruginosa in a neonatal intensive care unit: molecular epidemiology and infection control measures. BMC Infect. Dis. 9:70. http://dx.doi.org/10.1186/1471-2334-9-70.
87. Hota S, Hirji Z, Stockton K, Lemieux C, Dedier H, Wolfaardt G, Gardam MA. 2009. Outbreak of multidrug-resistant Pseudomonas aeruginosa colonization and infection secondary to imperfect intensive care unit room design. Infect. Control Hosp. Epidemiol. 30:25-33. http://dx.doi.org/10.1086/592700.
88. Mayank D, Anshuman M, Singh RK, Afzal A, Baronia AK, Prasad KN. 2009. Nosocomial cross-transmission of Pseudomonas aeruginosa between patients in a tertiary intensive care unit. Indian J. Pathol. Microbiol. 52:509-513. http://dx.doi.org/10.4103/0377-4929.56143.
89. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J, Velez JD, Castaneda CR, Recalde M, Livermore DM. 2004. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J. Clin. Microbiol. 42:5094-5101. http://dx.doi.org/10.1128/JCM.42.11.5094-5101.2004.
90. Boutiba-Ben Boubaker I, Boukadida J, Triki O, Hannachi N, Ben Redjeb S. 2003. Outbreak of nosocomial urinary tract infections due to a multidrug resistant Pseudomonas aeruginosa. Pathol. Biol. (Paris) 51:147-150. (In French.). http://dx.doi.org/10.1016/S0369-8114(03)00040-3.
91. Bertrand X, Bailly P, Blasco G, Balvay P, Boillot A, Talon D. 2000. Large outbreak in a surgical intensive care unit of colonization or infection with Pseudomonas aeruginosa that overexpressed an active efflux pump. Clin. Infect. Dis. 31:E9-E14. http://dx.doi.org/10.1086/318117.
92. Bert F, Maubec E, Bruneau B, Berry P, Lambert-Zechovsky N. 1998. Multi-resistant Pseudomonas aeruginosa outbreak associated with contaminated tap water in a neurosurgery intensive care unit. J. Hosp. Infect. 39:53-62. http://dx.doi.org/10.1016/S0195-6701(98)90243-2.
93. Griffith SJ, Nathan C, Selander RK, Chamberlin W, Gordon S, Kabins S, Weinstein RA. 1989. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital. J. Infect. Dis. 160:1030-1036. http://dx.doi.org/10.1093/infdis/160.6.1030.
94. DiazGranados CA, Jones MY, Kongphet-Tran T, White N, Shapiro M, Wang YF, Ray SM, Blumberg HM. 2009. Outbreak of Pseudomonas aeruginosa infection associated with contamination of a flexible bronchoscope. Infect. Control Hosp. Epidemiol. 30:550-555. http://dx.doi.org/10.1086/597235.
95. Sorin M, Segal-Maurer S, Mariano N, Urban C, Combest A, Rahal JJ. 2001. Nosocomial transmission of imipenem-resistant Pseudomonas aeruginosa following bronchoscopy associated with improper connection to the Steris System 1 processor. Infect. Control Hosp. Epidemiol. 22:409-413. http://dx.doi.org/10. 1086/501925.
96. Panzig B, Schroder G, Pitten FA, Grundling M. 1999. A large outbreak of multiresistant Pseudomonas aeruginosa strains in north-eastern Germany. J. Antimicrob. Chemother. 43:415-418. http://dx.doi.org/10.1093/jac/43.3.415.
97. Fraser TG, Reiner S, Malczynski M, Yarnold PR, Warren J, Noskin GA. 2004. Multidrug-resistant Pseudomonas aeruginosa cholangitis after endoscopic retrograde cholangiopancreatography: failure of routine endoscope cultures to prevent an outbreak. Infect. Control Hosp. Epidemiol. 25:856-859. http://dx.doi.org/10.1086/502309.
98. Pitten FA, Panzig B, Schroder G, Tietze K, Kramer A. 2001. Transmission of a multiresistant Pseudomonas aeruginosa strain at a German university hospital. J. Hosp. Infect. 47:125-130. http://dx.doi.org/10.1053/jhin.2000.0880.
99. Bukholm G, Tannaes T, Kjelsberg AB, Smith-Erichsen N. 2002. An outbreak of multidrug-resistant Pseudomonas aeruginosa associated with increased risk of patient death in an intensive care unit. Infect. Control Hosp. Epidemiol. 23:441-446. http://dx.doi.org/10.1086/502082.
100. Leung CH, Wang NY, Liu CP, Weng LC, Hsieh FC, Lee CM. 2008. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan. J. Microbiol. Immunol. Infect. 41:491-498.
101. Verweij PE, Bijl D, Melchers WJ, De Pauw BE, Meis JF, Hoogkamp-Korstanje JA, Voss A. 1997. Pseudo-outbreak of multiresistant Pseudomonas aeruginosa in a hematology unit. Infect. Control Hosp. Epidemiol. 18:128-131. http://dx.doi.org/10.1086/647567.
102. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S. 2002. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch. Intern. Med. 162:1515-1520. http://dx.doi.org/10.1001/archinte.162.13.1515.
103. Vilar-Compte D, Jacquemin B, Diaz-Gonzalez A, Velasquez C, Volkow P. 2003. Pseudomonas aeruginosa outbreak, in the area of surgical wound ambulatory care, in postmastectomy patients. Salud Publica Mex. 45:371-378. (In Spanish.) http://dx.doi.org/10.1590/S0036-36342003000500007.
104. Zheng YN, Xu ZY, Weng XH. 1990. Experimental study and case control study of nosocomial infection caused by Pseudomonas aeruginosa. Zhonghua Nei Ke Za Zhi 29:217-220, 253. (In Chinese.
105. Gras-Le Guen C, Lepelletier D, Debillon T, Gournay V, Espaze E, Roze JC. 2003. Contamination of a milk bank pasteuriser causing a Pseudomonas aeruginosa outbreak in a neonatal intensive care unit. Arch. Dis. Child Fetal Neonatal Ed. 88:F434-F435. http://dx.doi.org/10.1136/fn.88.5.F434.
106. Kikuchi T, Nagashima G, Taguchi K, Kuraishi H, Nemoto H, Yamanaka M, Kawano R, Ugajin K, Tazawa S, Marumo K. 2007. Contaminated oral intubation equipment associated with an outbreak of carbapenem-resistant Pseudomonas in an intensive care unit. J. Hosp. Infect. 65:54-57. http://dx.doi.org/10.1016/j. jhin.2006.07.017.
107. Pena C, Dominguez MA, Pujol M, Verdaguer R, Gudiol F, Ariza J. 2003. An outbreak of carbapenem-resistant Pseudomonas aeruginosa in a urology ward. Clin. Microbiol. Infect. 9:938-943. http://dx.doi.org/10.1046/j.1469-0691.2003.00686. x.
108. Climo MW, Pastor A, Wong ES. 1997. An outbreak of Pseudomonas aeruginosa related to contaminated urodynamic equipment. Infect. Control Hosp. Epidemiol. 18:509-510. http://dx.doi.org/10.1086/647657.